All In Biotech

Drug Trial Radar · NCT07737795

Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer

A Single Arm Phase 2 Trial With a Safety Lead in Evaluating the Addition of OK-1 to Weekly Paclitaxel in Patients With Recurrent Endometrial Cancer

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Nov 2028

Study completion Nov 2029

Sponsor

Lead sponsor
University of OklahomaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Jul 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate whether treatment with the investigational drug OK-1 in combination with paclitaxel can reduce tumor burden in patients with advanced or recurrent endometrial cancer (A/R-EC).

Conditions

  • Endometrial Cancer

Interventions

  • OK-1 & PaclitaxelDrug

    OK-1 capsules will be administered orally at 3.5-4.5 mg/kg twice a day during a 21-day cycle (3 weeks on, one week off in a 28-day cycle) Other Names: • NSC 726189 Paclitaxel will be administered 60-70 mg/m2 IV on Day 1,8 and 15 (3 weeks on, one week off in a 28-day cycle)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and Proportion of Patients Who Safely Tolerate The Combination of OK-1 and PaclitaxelTime frame: 12 Months
  2. Proportion of Patients Who Successfully Completed The Safety Lead-In Phase and Tolerated OK-1 In Combination With Paclitaxel.Time frame: 1 Year
  3. Proportion of Participants Overrall Response Rate To OK-1 In Comination With PaclitaxelTime frame: 2 Years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • OU Health Stephenson Cancer Center

    Oklahoma City, Oklahoma · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.